Journal of epilepsy research最新文献

{"title":"Unlocking Comprehensive Epilepsy Care: The Dual Promise of Magnetoencephalography.","authors":"Dong Wook Kim","doi":"10.14581/jer.25009","DOIUrl":"10.14581/jer.25009","url":null,"abstract":"","PeriodicalId":73741,"journal":{"name":"Journal of epilepsy research","volume":"15 2","pages":"81-82"},"PeriodicalIF":0.0,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145812260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Assessment of Quality of Life and Serum S100B in Epilepsy Treated with Newer and Conventional Drugs: A Pharmacoeconomic Perspective.","authors":"Shivaraj, Anupam Prakash, Harmeet Singh Rehan, Lalit K Gupta","doi":"10.14581/jer.25011","DOIUrl":"10.14581/jer.25011","url":null,"abstract":"<p><strong>Background and purpose: </strong>S100B is a cytokine produced by astrocytes following glial and neuronal damage. This study aims to evaluate the impact of anti-epileptic drugs (AEDs) on serum S100B levels and health-related quality of life (HRQoL) indices.</p><p><strong>Methods: </strong>In this prospective observational study, serum S100B levels were compared between persons with epilepsy (PWE) and healthy controls. In the PWE group, serum S100B levels and HRQoL using patient weighted quality of life in epilepsy (QOLIE-10-P), pittsburgh sleep quality index (PSQI), and liverpool adverse event profile (LAEP) scores were assessed at baseline and after 12 weeks of AEDs treatment.</p><p><strong>Results: </strong>The mean baseline serum S100B level in the PWE group was 0.093±0.031 μg/L, significantly higher than in the control group, 0.050±0.020 μg/L. In PWE, after 12 weeks of treatment, this level decreased by 17.20% (<i>p</i><0.001). QOLIE-10-P scores showed improvement (32.1%; <i>p</i><0.001) across both conventional and newer AED types. PSQI scores improved by 6.9% with conventional AEDs (<i>p</i>=0.19) and 35.7% with newer AEDs (<i>p</i><0.001). LAEP scores increased by 5.06% with conventional AEDs (<i>p</i>=0.06) and decreased by 5.63% with newer AEDs (<i>p</i>=0.10). Seizures were significantly reduced in both groups (overall 86.09%). Treatment costs were higher for newer AEDs ($39.10) than for conventional AEDs ($16.73).</p><p><strong>Conclusions: </strong>Over 12 weeks of AED therapy, PWE demonstrated significant reductions in both serum S100B levels and seizure frequency. While conventional and newer AEDs yielded comparable improvements in HRQoL, newer AEDs conferred an advantage in sleep quality.</p>","PeriodicalId":73741,"journal":{"name":"Journal of epilepsy research","volume":"15 2","pages":"93-103"},"PeriodicalIF":0.0,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145812237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Notice: Anti-kindling Effect of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in Pentylenetetrazole Induced Kindling Seizure Model.","authors":"Lekha Saha, Swati Bhandari, Alka Bhatia, Dibyajyoti Banerjee, Amitava Chakrabarti","doi":"10.14581/jer.14011.r1","DOIUrl":"https://doi.org/10.14581/jer.14011.r1","url":null,"abstract":"<p><p>[This retracts the article on p. 45 in vol. 4, PMID: 25625088.].</p>","PeriodicalId":73741,"journal":{"name":"Journal of epilepsy research","volume":"15 2","pages":"117"},"PeriodicalIF":0.0,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145812225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Brain Stimulation Therapy for Drug-Resistant Epilepsy: Present and Future Perspectives.","authors":"Young-Min Shon, Hea Ree Park, Seunghoon Lee","doi":"10.14581/jer.25004","DOIUrl":"10.14581/jer.25004","url":null,"abstract":"<p><p>Drug-resistant epilepsy (DRE) remains a formidable clinical challenge, affecting nearly 30-40% of patients despite optimized pharmacotherapy. In patients for whom resective surgery is contraindicated or poses unacceptable risks, neuromodulatory therapies-most notably deep brain stimulation (DBS)-have emerged as viable and reversible treatment options. This narrative review critically examines the current applications of DBS for DRE, with a focus on major targets including the anterior thalamic nucleus, centromedian nucleus, hippocampus, and emerging targets such as the pulvinar. We provide an in-depth discussion of the therapeutic mechanisms underlying DBS-from local cellular inhibition and desynchronization to widespread network modulation and neuroplasticity induction-and review the latest advances in sensing technologies, patient-specific connectivity mapping, and closed loop stimulation paradigms. In addition to integrating data from randomized controlled trials, long-term observational studies, and advanced imaging investigations, we discuss limitations, persistent challenges, and future research directions that will guide clinical decision-making and optimize therapeutic outcomes.</p>","PeriodicalId":73741,"journal":{"name":"Journal of epilepsy research","volume":"15 1","pages":"33-41"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stigmas in Epilepsy: Systematic Review and Meta-Analysis.","authors":"Matheus Henrique Leite E Silva, João Vitor Sabadine Lima, Iza Paula da Silva Lopes, Ana Carolina Valgas da Silva, Isabela Magalhães Lucchi, Gabriela Padovani Oliveira, Luam Anacleto Mandonça Vieira, Guilherme Octávio Martins Bruno, Elisa de Paula França Resende","doi":"10.14581/jer.25003","DOIUrl":"10.14581/jer.25003","url":null,"abstract":"<p><p>Recent research has disclosed significant associations between stigma suffered by people living with epilepsy (PWE) and psychiatric conditions, especially major depression. These results have practical implication when coupled with the precise regional-and-local prevalences of stigma in its heterogeneous manifestations among PWE. Here we review current research involving stigma in PWE to assess its prevalence and explore psychopathological associations. A systematic review was conducted in PubMed and Scopus to identify clinical trials objectively evaluating prevalence of any type of stigma, enacted and perceived, in PWE, published from database inception to 31 May 2024. A random effects meta-analysis was undertaken, with 6,072 participants, to obtain the meta-prevalence of stigma among PWE. Subgroup analysis moderated by major continent was delineated. A report was obtained from clinical documentation review and adjoined to the evidence generated. From the 105 records identified, 22 studies were eligible for inclusion. The meta-analysis revealed an overall stigma prevalence of 35% (29%; 41%), and subgroups, Africa or Asia (mostly); arbitrarily defined after analysis of geographical study distributions; indicated a prevalence of 40% (34%; 46%) and 28% (21%; 37%), respectively. Significant difference was identified (<i>p</i>=0.03). The case reported exemplifies how stigma may impair development, especially in children and adolescents. Stigmas among PWE are prevalent. More than one in three PWE has already experienced some form of stigma and there is potential to undermine quality of life and associate with psychiatric disorders. PWE may benefit from tailored screening and management approaches to decrease stigma burden.</p>","PeriodicalId":73741,"journal":{"name":"Journal of epilepsy research","volume":"15 1","pages":"23-32"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brivaracetam, Another Useful Antiseizure Medication.","authors":"Dong Wook Kim","doi":"10.14581/jer.25001","DOIUrl":"10.14581/jer.25001","url":null,"abstract":"","PeriodicalId":73741,"journal":{"name":"Journal of epilepsy research","volume":"15 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in Epilepsy: A Systemic Review.","authors":"Almuntasar Al-Breiki, Said Al-Sinani, Ahmed Elsharaawy, Mohamed Usama, Tariq Al-Saadi","doi":"10.14581/jer.25002","DOIUrl":"10.14581/jer.25002","url":null,"abstract":"<p><p>Diagnosing and managing epilepsy is difficult for doctors. Surgery can help some patients, but it often takes a long time to get there. This research looks at scientific studies to see if artificial intelligence and machine learning (ML) can be used to improve epilepsy treatment. In-depth research was conducted across PubMed, Google Scholar, Scopus, Wiley, Web of Science, and Microsoft Academia. This search focused on studies exploring the use of ML for diagnosing epilepsy, predicting treatment response, and predicting outcomes of epilepsy surgery. The search was limited to original English-language articles published between 2015 and 2022. This review examined 36 studies on using ML to predict epilepsy. The studies fell into four categories: general diagnosis (27), treatment outcome (3), identifying surgical candidates (2), and predicting surgical results (4). Researchers employed a diverse set of data, including symptoms and brain scans, alongside machine learning algorithms like support vector machines and convolutional neural networks, to construct their models. Some models achieved impressive results with areas under the curve reaching up to 0.99, but most studies were limited by small sample sizes and a lack of independent validation. ML shows potential for epilepsy treatment based on initial studies, but real-world use is restricted due to small sample sizes and the need for more validation from other studies. Large collaborative research efforts and data on long-term outcomes are essential before ML can be widely adopted by doctors and make a positive difference for epilepsy patients.</p>","PeriodicalId":73741,"journal":{"name":"Journal of epilepsy research","volume":"15 1","pages":"2-22"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Ketamine Needs Caution in NMDA-R Encephalitis Related Status Epilepticus.","authors":"Samhita Panda, Krishna Kanth Ravi, Rohit Kushwah, Sameer Taywade, Sarbesh Tiwari","doi":"10.14581/jer.25008","DOIUrl":"10.14581/jer.25008","url":null,"abstract":"<p><p>Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is characterised by the antibodies decreasing the NMDAR surface density and synaptic localization by selective antibody-mediated capping and internalization of surface NMDAR. Ketamine is a NMDAR antagonist which can produce dose-dependent, self-limiting side effects such as hypersalivation, hyperreflexia, transient clonus, dizziness, nausea, vomiting, tachycardia, hypertension, and detrusor muscle overactivity. A 22-year-old girl presented with recent onset behavioral change, progressive movement disorder and later lapsed into super refractory status epilepticus (SRSE). She was treated with at least four antiseizure medications, immunomodulation as well as anesthetic drugs with only partial relief in status. Ketamine was added for SRSE and led to a significant worsening of clinical symptoms with abatement after stopping. She finally responded to thiopentone infusion. Ketamine has been found to be beneficial in SRSE in encephalitis including anti-NMDAR encephalitis. This is seemingly counterintuitive given how the action of the drug mimics the pathophysiology of the disease. This report highlights the risk of paroxysmal sympathetic hyperactivity and aggravation of clinical and electrographic features of anti-NMDAR encephalitis with ketamine. Hence, ketamine and similar medications acting on the NMDAR should be used with caution in anti-NMDAR encephalitis.</p>","PeriodicalId":73741,"journal":{"name":"Journal of epilepsy research","volume":"15 1","pages":"76-79"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Medicinal Cannabis for Epilepsy in the Australian Community 2023-2024: A Cross-Sectional Survey.","authors":"Douglas A D Skene, Iain S McGregor, Lisa Todd, Anastasia Suraev","doi":"10.14581/jer.25006","DOIUrl":"10.14581/jer.25006","url":null,"abstract":"<p><strong>Background and purpose: </strong>Epilepsy is a common indication for medicinal cannabis (MC) prescription in Australia. Despite legal MC products being available for 8 years, some individuals continue to rely on illicit cannabis. Here, we conducted a survey of Australian persons/people with epilepsy (PWE) and caregivers of a PWE to assess whether the current legal framework supports PWE and/or their caregivers to access prescribed MC.</p><p><strong>Methods: </strong>The cross-sectional survey consisted of five sections examining sociodemographics, medical history, history of MC use, attitudes towards MC, and barriers to accessing MC.</p><p><strong>Results: </strong>Of the 126 respondents included in these analyses, 102 were PWE (mean age, 40.9±12.3 years) and 24 were caregivers of a PWE (mean age of PWE, 14.1±8.9 years). Among PWE, 27.5% (28/102) had only used illicit MC products, 27.5% (28/102) had transitioned to prescribed MC products, and 16.7% (17/102) used both. Most caregivers 70.8% (17/24) had only accessed prescribed MC products. Most respondents 77.0% (97/126) reported using MC as an adjunct to conventional anti-seizure medications. Caregivers were more likely to administer prescribed high-cannabidiol products to children using oral routes of administration (<i>p</i><0.001). In contrast, PWE often used inhaled cannabis (<i>p</i><0.001). Overall, 67.0% (83/124) of respondents reported that MC \"improved\" or \"greatly improved\" their epilepsy, irrespective of MC type. The main barrier to accessing prescribed MC was \"cost\" (69.0%, 87/126), while tetrahydrocannabinol (THC)-related driving restrictions were also a significant concern for PWE.</p><p><strong>Conclusions: </strong>The current regulatory framework in Australia supports MC access for PWE and their caregivers, primarily through cannabis clinics. However, cost remains a significant concern. The prevalent use of Δ9-THC-containing and inhaled MC products, either illicit or prescribed, highlights the urgent need to further investigate their safety and efficacy in epilepsy.</p>","PeriodicalId":73741,"journal":{"name":"Journal of epilepsy research","volume":"15 1","pages":"56-69"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brivaracetam: Pharmacology, Clinical Efficacy, and Safety in Epilepsy.","authors":"Heewon Hwang, Won-Joo Kim","doi":"10.14581/jer.25005","DOIUrl":"10.14581/jer.25005","url":null,"abstract":"<p><p>Brivaracetam, a high-affinity synaptic vesicle 2A (SV2A) ligand and propyl analog of levetiracetam, has been approved as an adjunctive and monotherapy option for focal onset seizures in various age groups. This review synthesizes data from both clinical trials and real-world studies to evaluate brivaracetam's efficacy, safety, and tolerability profile. Notably, brivaracetam's rapid penetration across the blood-brain barrier, selective SV2A binding, and favorable pharmacokinetic properties contribute to its robust seizure control capabilities, setting it apart from other antiseizure medications. Studies have shown that brivaracetam consistently achieves significant seizure frequency reductions and high responder rates, demonstrating strong efficacy and an overall favorable safety profile. Importantly, brivaracetam also demonstrates effectiveness in special populations, including older individuals and patients with post-stroke epilepsy, maintaining good tolerability and favorable outcomes and achieving high rates of seizure freedom. Future research should further investigate brivaracetam's utility in broader patient groups to better understand its long-term safety and expand its therapeutic reach. With its unique pharmacological properties, clinical flexibility, and promising safety profile, brivaracetam stands as a valuable addition to current epilepsy treatment options, addressing several unmet needs in seizure management.</p>","PeriodicalId":73741,"journal":{"name":"Journal of epilepsy research","volume":"15 1","pages":"42-55"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}